Published in Cancer Chemother Pharmacol on August 08, 2010
Vitamin C: a concentration-function approach yields pharmacology and therapeutic discoveries. Adv Nutr (2011) 1.45
Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer. Free Radic Biol Med (2011) 1.27
Parenteral ascorbate as a cancer therapeutic: a reassessment based on pharmacokinetics. Antioxid Redox Signal (2013) 0.97
Clinical experience with intravenous administration of ascorbic acid: achievable levels in blood for different states of inflammation and disease in cancer patients. J Transl Med (2013) 0.90
Ascorbic acid and a cytostatic inhibitor of glycolysis synergistically induce apoptosis in non-small cell lung cancer cells. PLoS One (2013) 0.90
A combination of two antioxidants (an SOD mimic and ascorbate) produces a pro-oxidative effect forcing Escherichia coli to adapt via induction of oxyR regulon. Anticancer Agents Med Chem (2011) 0.89
Osteoblast-secreted collagen upregulates paracrine Sonic hedgehog signaling by prostate cancer cells and enhances osteoblast differentiation. Mol Cancer (2012) 0.88
Walnuts have potential for cancer prevention and treatment in mice. J Nutr (2014) 0.82
Ascorbate as a co-factor for fe- and 2-oxoglutarate dependent dioxygenases: physiological activity in tumor growth and progression. Front Oncol (2014) 0.81
Ascorbic acid has superior ex vivo antiproliferative, cell death-inducing and immunomodulatory effects over IFN-α in HTLV-1-associated myelopathy. PLoS Negl Trop Dis (2012) 0.81
Intravenous ascorbic acid to prevent and treat cancer-associated sepsis? J Transl Med (2011) 0.81
Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid. Antimicrob Agents Chemother (2013) 0.80
High-dose intravenous vitamin C combined with cytotoxic chemotherapy in patients with advanced cancer: a phase I-II clinical trial. PLoS One (2015) 0.77
Praziquantel synergistically enhances paclitaxel efficacy to inhibit cancer cell growth. PLoS One (2012) 0.76
Pharmacological doses of daily ascorbate protect tumors from radiation damage after a single dose of radiation in an intracranial mouse glioma model. Front Oncol (2014) 0.75
GSTP1 and GSTO1 single nucleotide polymorphisms and the response of bladder cancer patients to intravesical chemotherapy. Sci Rep (2015) 0.75
Synergistic Enhancement of Topotecan-Induced Cell Death by Ascorbic Acid in Human Breast MCF-7 Tumor Cells. Free Radic Biol Med (2017) 0.75
Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst (2008) 5.09
HIF-dependent antitumorigenic effect of antioxidants in vivo. Cancer Cell (2007) 4.81
Vitamin C pharmacokinetics: implications for oral and intravenous use. Ann Intern Med (2004) 4.30
High-dose vitamin C versus placebo in the treatment of patients with advanced cancer who have had no prior chemotherapy. A randomized double-blind comparison. N Engl J Med (1985) 3.36
Pharmacologic ascorbic acid concentrations selectively kill cancer cells: action as a pro-drug to deliver hydrogen peroxide to tissues. Proc Natl Acad Sci U S A (2005) 3.30
Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A (1978) 3.14
Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivo. Proc Natl Acad Sci U S A (2007) 2.71
Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer. A controlled trial. N Engl J Med (1979) 2.63
Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A (2008) 2.50
The Hill equation: a review of its capabilities in pharmacological modelling. Fundam Clin Pharmacol (2008) 2.44
Phase I clinical trial of i.v. ascorbic acid in advanced malignancy. Ann Oncol (2008) 2.27
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res (2008) 1.98
Mammalian facilitative hexose transporters mediate the transport of dehydroascorbic acid. Nature (1993) 1.97
Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood (1999) 1.83
Mechanisms of ascorbate-induced cytotoxicity in pancreatic cancer. Clin Cancer Res (2010) 1.57
Ascorbic acid (vitamin C) improves the antineoplastic activity of doxorubicin, cisplatin, and paclitaxel in human breast carcinoma cells in vitro. Cancer Lett (1996) 1.28
Overexpression and involvement of special AT-rich sequence binding protein 1 in multidrug resistance in human breast carcinoma cells. Cancer Sci (2009) 1.21
Vitamin C suppresses proliferation of the human melanoma cell SK-MEL-2 through the inhibition of cyclooxygenase-2 (COX-2) expression and the modulation of insulin-like growth factor II (IGF-II) production. J Cell Physiol (2008) 1.13
Stromal cell oxidation: a mechanism by which tumors obtain vitamin C. Cancer Res (1999) 1.13
Human HL-60 myeloid leukemia cells transport dehydroascorbic acid via the glucose transporters and accumulate reduced ascorbic acid. Blood (1994) 1.08
Losing and finding a way at C: new promise for pharmacologic ascorbate in cancer treatment. Free Radic Biol Med (2009) 1.05
Antiproliferative effect of ascorbic acid is associated with the inhibition of genes necessary to cell cycle progression. PLoS One (2009) 1.00
The molecular mechanisms of vitamin C on cell cycle regulation in B16F10 murine melanoma. J Cell Biochem (2007) 0.97
Cytotoxic effects of 27 anticancer drugs in HeLa and MDR1-overexpressing derivative cell lines. Biol Pharm Bull (2002) 0.96
Recycling of vitamin C by a bystander effect. J Biol Chem (2002) 0.95
Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Cancer Res (2007) 0.94
Biological nature of the effect of ascorbic acids on the growth of human leukemic cells. Cancer Res (1985) 0.91
Sodium ascorbate inhibits growth via the induction of cell cycle arrest and apoptosis in human malignant melanoma A375.S2 cells. Melanoma Res (2006) 0.88
Mitochondria as targets for established and novel anti-cancer agents. Drug Resist Updat (2001) 0.88
Sodium ascorbate induces apoptosis in neuroblastoma cell lines by interfering with iron uptake. Mol Cancer (2007) 0.87
Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun (2004) 0.86
Ascorbate (vitamin C) induces cell death through the apoptosis-inducing factor in human breast cancer cells. Oncol Rep (2007) 0.86
Vitamin C enhances chemosensitization of esophageal cancer cells in vitro. J Chemother (2005) 0.84
Effects of high dose ascorbate administration on L-10 tumor growth in guinea pigs. P R Health Sci J (2005) 0.82
Comment re: Vitamin C antagonizes the cytotoxic effects of chemotherapy. Cancer Res (2009) 0.82
Oxidative stress leads to a rapid alteration of transferrin receptor intravesicular trafficking. Exp Cell Res (1998) 0.81
Growth modulation of human leukemic, preleukemic, and myeloma progenitor cells by L-ascorbic acid. Am J Clin Nutr (1991) 0.79
Erlotinib activates mitochondrial death pathways related to the production of reactive oxygen species in the human non-small cell lung cancer cell line A549. Clin Exp Pharmacol Physiol (2008) 0.78
Ascorbic acid recycling in Nb2 lymphoma cells: implications for tumor progression. Free Radic Biol Med (1999) 0.78
Chemosensitizing effect of vitamin C in combination with 5-fluorouracil in vitro. In Vivo (2003) 0.77
MicroRNA replacement therapy for miR-145 and miR-33a is efficacious in a model of colon carcinoma. Cancer Res (2011) 1.79
RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther (2006) 1.65
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung. Eur J Pharm Biopharm (2010) 1.49
A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes. J Control Release (2006) 1.37
The host defence peptide LL-37/hCAP-18 is a growth factor for lung cancer cells. Lung Cancer (2007) 1.36
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth. J Biol Chem (2002) 1.25
Poly(vinyl alcohol) nanofibers by electrospinning as a protein delivery system and the retardation of enzyme release by additional polymer coatings. Biomacromolecules (2005) 1.22
In vivo pharmacokinetics, tissue distribution and underlying mechanisms of various PEI(-PEG)/siRNA complexes. Toxicol Appl Pharmacol (2009) 1.21
Retracted Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol Endocrinol (2003) 1.19
HMGA2 gene is a promising target for ovarian cancer silencing therapy. Int J Cancer (2008) 1.13
In vitro MR imaging of regulated gene expression. Radiology (2003) 1.12
Matrix metalloproteinases 2 and 9 mediate epidermal growth factor receptor transactivation by gonadotropin-releasing hormone. J Biol Chem (2003) 1.11
Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials (2010) 1.09
PEG grafting of polyethylenimine (PEI) exerts different effects on DNA transfection and siRNA-induced gene targeting efficacy. J Drug Target (2008) 1.04
The fibroblast growth factor-binding protein FGF-BP. Int J Biochem Cell Biol (2005) 1.03
Intravenous vitamin C in the treatment of shingles: results of a multicenter prospective cohort study. Med Sci Monit (2012) 1.02
Polyethylenimine/small interfering RNA-mediated knockdown of vascular endothelial growth factor in vivo exerts anti-tumor effects synergistically with Bevacizumab. J Gene Med (2010) 1.01
RNA interference targeting survivin exerts antitumoral effects in vitro and in established glioma xenografts in vivo. Neuro Oncol (2011) 0.99
Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia (2009) 0.97
Functional role and therapeutic potential of the pim-1 kinase in colon carcinoma. Neoplasia (2013) 0.94
Expression and function of the receptor protein tyrosine phosphatase zeta and its ligand pleiotrophin in human astrocytomas. J Neuropathol Exp Neurol (2003) 0.94
Depletion of the transcriptional coactivators megakaryoblastic leukaemia 1 and 2 abolishes hepatocellular carcinoma xenograft growth by inducing oncogene-induced senescence. EMBO Mol Med (2013) 0.92
Polyethylenimines for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.91
Physicochemical and biological characterization of polyethylenimine-graft-poly(ethylene glycol) block copolymers as a delivery system for oligonucleotides and ribozymes. Bioconjug Chem (2004) 0.91
Polyethylenimine (PEI)/siRNA-mediated gene knockdown in vitro and in vivo. Methods Mol Biol (2010) 0.90
Ribozyme-targeting reveals the rate-limiting role of pleiotrophin in glioblastoma. Int J Cancer (2005) 0.90
Polyethylenimine PEI F25-LMW allows the long-term storage of frozen complexes as fully active reagents in siRNA-mediated gene targeting and DNA delivery. Eur J Pharm Biopharm (2008) 0.89
Retracted Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene (2003) 0.89
Effects on neurite outgrowth and cell survival of a secreted fibroblast growth factor binding protein upregulated during spinal cord injury. Am J Physiol Regul Integr Comp Physiol (2007) 0.89
Inhibition of endogenous carcinoembryonic antigen (CEA) increases the apoptotic rate of colon cancer cells and inhibits metastatic tumor growth. Clin Exp Metastasis (2002) 0.89
MicroRNAs (miRNAs) in colorectal cancer: from aberrant expression towards therapy. Curr Pharm Des (2013) 0.88
Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Res (2003) 0.88
Critical role of G(alpha)12 and G(alpha)13 for human small cell lung cancer cell proliferation in vitro and tumor growth in vivo. Clin Cancer Res (2010) 0.86
Cytotoxicity of the novel anti-cancer drug rViscumin depends on HER-2 levels in SKOV-3 cells. Biochem Biophys Res Commun (2004) 0.86
Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing. Neoplasia (2004) 0.85
Effect of the sterilization method on the performance of collagen type I on chronic wound parameters in vitro. J Biomed Mater Res B Appl Biomater (2009) 0.85
Multiple effects of the special AT-rich binding protein 1 (SATB1) in colon carcinoma. Int J Cancer (2014) 0.85
Analysis of transcriptional regulation of the human miR-17-92 cluster; evidence for involvement of Pim-1. Int J Mol Sci (2013) 0.85
Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradation. Eur J Pharm Biopharm (2004) 0.84
In vitro cytotoxic and immunomodulatory profiling of low molecular weight polyethylenimines for pulmonary application. Toxicol In Vitro (2009) 0.84
A sensitive polymerase chain reaction-based method for detection and quantification of metastasis in human xenograft mouse models. Clin Exp Metastasis (2010) 0.84
Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Maltose- and maltotriose-modified, hyperbranched poly(ethylene imine)s (OM-PEIs): Physicochemical and biological properties of DNA and siRNA complexes. J Control Release (2010) 0.83
Immunolocalization of an FGF-binding protein reveals a widespread expression pattern during different stages of mouse embryo development. Histochem Cell Biol (2001) 0.83
Stimulation of the chemosensory TRPA1 cation channel by volatile toxic substances promotes cell survival of small cell lung cancer cells. Biochem Pharmacol (2012) 0.83
Modulation of the γ-aminobutyric acid (GABA) system by Passiflora incarnata L. Phytother Res (2010) 0.82
Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities. Toxicol In Vitro (2010) 0.82
U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastoma. Nucleic Acid Ther (2013) 0.81
Stabilization of oligonucleotide-polyethylenimine complexes by freeze-drying: physicochemical and biological characterization. J Control Release (2004) 0.80
Ribozyme-targeting of a secreted FGF-binding protein (FGF-BP) inhibits proliferation of prostate cancer cells in vitro and in vivo. Oncogene (2002) 0.80
Early effect of NEURAPAS® balance on current source density (CSD) of human EEG. BMC Psychiatry (2011) 0.79
PEI-complexed LNA antiseeds as miRNA inhibitors. RNA Biol (2012) 0.79
The neural crest transcription factor Brn3a is expressed in melanoma and required for cell cycle progression and survival. EMBO Mol Med (2013) 0.79
Hyperbranched PEI with various oligosaccharide architectures: synthesis, characterization, ATP complexation, and cellular uptake properties. Biomacromolecules (2009) 0.78
Anti-tumor effects of fibroblast growth factor-binding protein (FGF-BP) knockdown in colon carcinoma. Mol Cancer (2011) 0.78
Molecular targets of the antiinflammatory Harpagophytum procumbens (devil's claw): inhibition of TNFα and COX-2 gene expression by preventing activation of AP-1. Phytother Res (2011) 0.78
Biocompatibility and efficacy of oligomaltose-grafted poly(ethylene imine)s (OM-PEIs) for in vivo gene delivery. Mol Pharm (2013) 0.77
Simvastatin suppresses head and neck squamous cell carcinoma ex vivo and enhances the cytostatic effects of chemotherapeutics. Cancer Chemother Pharmacol (2014) 0.77
Therapeutic targeting of the mitotic spindle checkpoint through nanoparticle-mediated siRNA delivery inhibits tumor growth in vivo. Cancer Lett (2011) 0.77
Nonviral delivery platform for therapeutic RNAi: pegylated siRNA/cationic liposome complexes for targeting of the proto-oncogene bcl-2. Future Oncol (2009) 0.77
Tau silencing by siRNA in the P301S mouse model of tauopathy. Curr Gene Ther (2014) 0.76
Herbal triplet in treatment of nervous agitation in children. Wien Med Wochenschr (2012) 0.75
The chorioallantoic membrane assay is a promising ex vivo model system for the study of vascular anomalies. In Vivo (2013) 0.75
Polymer-based delivery of RNA-based therapeutics in ovarian cancer. Methods Mol Biol (2013) 0.75
Heregulin-beta1 regulates the estrogen receptor-alpha gene expression and activity via the ErbB2/PI 3-K/Akt pathway. Oncogene (2005) 0.75
A chorioallantoic membrane model for the determination of anti-angiogenic effects of imatinib. Eur J Pharm Biopharm (2013) 0.75
Degradable and biocompatible poly(N,N-dimethylaminoethyl methacrylate-co-caprolactone)s as DNA transfection agents. Macromol Biosci (2013) 0.75
A novel method for the assessment of targeted PEI-based nanoparticle binding based on a static surface plasmon resonance system. Anal Chem (2013) 0.75